Report - Bevacizumab, 10 años aportando supervivencia en el cáncer ......Xeloda + Beva (n=140) Xeloda (n=140) Median PFS (months) 9.1 5.1 HR (95% CI, p value) 0.53 (0.41‒0.69, p

Select PornographicDefamatoryIllegal/UnlawfulSpamOther Terms Of Service ViolationFile a copyright complaint

Please pass captcha verification before submit form